India: A recent cross-sectional study conducted in Maharashtra, India, has shed light on the association between high-risk ...
Public health stakeholders, during a consultative workshop, reaffirmed their commitment of fully supporting the successful ...
PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...
We are currently undergoing maintenance on some services, which may temporarily affect access to subscription accounts and ...
Ontario will replace its main method of cervical cancer screening next week to a more accurate and less frequent test, but the dreaded speculum exam is not in the rear-view yet.
If approved, PRGN-2012 would be the first treatment allowed by the FDA for the rare and chronic disease caused by HPV 6 and HPV 11.
Gynecologist Dr. Kim Alexander explains the benefits of HPV testing and midlife vaccination against the virus.